Abstract Objective To study the clinical features, treatment, and prognosis of neonates with Kasabach-Merritt syndrome (KMS), and to provide a reference for optimizing the diagnosis and treatment of this disease. Methods A retrospective analysis was performed for the clinical and follow-up data of 16 neonates with KMS who were admitted to the Anhui Children's Hospital, Anhui Medical University, from January 2016 to December 2020. Results Of the 16 neonates, there were 13 boys (81%) and 3 girls (19%), with an age of 1 hour to 10 days on admission. Among these neonates, 13 (81%) had cutaneous hemangioma (2 in the head and face, 5 in the trunk, and 6 in the extremities) and 3 (19%) had liver hemangioma. The main clinical manifestations of bleeding tendency and scattered petechiae and ecchymosis were observed in 10 neonates (62%). All the 16 neonates had varying degrees of thrombocytopenia and coagulation disorders. They all received glucocorticoid treatment after admission and 7 (44%) of them had response, among whom 4 experienced recurrence. Among the neonates with no response to glucocorticoid treatment, 3 received sirolimus treatment, among whom 1 had the tumor volume reduced by 58.8% after 4 weeks of treatment, with platelet count and coagulation function returning to normal, while 2 had no significant reduction in tumor volume or significant increase in platelet count and achieved a tumor volume reduced by (43.7±0.4)% after 4 weeks of combined treatment with bleomycin arterial embolization, with platelet count and coagulation function returning to normal. After 4 weeks of bleomycin arterial embolization alone for 4 neonates, tumor volume was reduced by (52.0±3.4)%, and platelet count and coagulation function returned to normal. Blunt and sharp dissection was performed for 2 neonates. The tumor was removed completely during surgery in the 2 neonates, with no infection or recurrence after surgery, and platelet count and coagulation function returned to normal. The postoperative pathological examination showed Kaposiform hemangioendothelioma in 1 out of the 2 neonates. Conclusions KMS has characteristic clinical manifestations, histopathological features, and laboratory examination results. The KMS neonates who are not sensitive to glucocorticoids can achieve a good curative effect through arterial embolization and sirolimus treatment.
Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura:report of a case[J]. Am J Dis Child, 1940, 59(3):1063-1070. DOI:10.1001/archpedi.1940.01990160135009.
[2]
Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma[J]. Plast Reconstr Surg, 1997, 100(6):1377-1386. DOI:10.1097/00006534-199711000-00001. PMID:9385948.
[3]
Radović SV, Kolinović M, Ljubić D. Propranolol in the preoperative treatment of Kasabach-Merritt syndrome:a case report[J]. J Med Case Rep, 2017, 11(1):308. DOI:10.1186/s13256-017-1475-0. PMID:29073926. PMCID:PMC5658992.
[4]
O'Rafferty C, O'Regan GM, Irvine AD, et al. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon[J]. Br J Haematol, 2015, 171(1):38-51. DOI:10.1111/bjh.13557. PMID:26123689.
[5]
Ji Y, Chen SY, Yang KY, et al. Kaposiform hemangioendothelioma:current knowledge and future perspectives[J]. Orphanet J Rare Dis, 2020, 15(1):39. DOI:10.1186/s13023-020-1320-1. PMID:32014025. PMCID:PMC6998257.
[6]
Wang Y, Kong LL, Sun BH, et al. Sirolimus for Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in two infants[J]. J Craniofac Surg, 2020, 31(4):1074-1077. DOI:10.1097/SCS.0000000000006301. PMID:32176003.
[7]
Wang P, Zhou W, Tao L, et al. Clinical analysis of Kasabach-Merritt syndrome in 17 neonates[J]. BMC Pediatr, 2014, 14:146. DOI:10.1186/1471-2431-14-146. PMID:24920221. PMCID:PMC4088914.
Schmid I, Klenk AK, Sparber-Sauer M, et al. Kaposiform hemangioendothelioma in children:a benign vascular tumor with multiple treatment options[J]. World J Pediatr, 2018, 14(4):322-329. DOI:10.1007/s12519-018-0171-5. PMID:30054848.
Cabrera TB, Speer AL, Greives MR, et al. Sirolimus for Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in a neonate[J]. AJP Rep, 2020, 10(4):e390-e394. DOI:10.1055/s-0040-1718901. PMID:33214934. PMCID:PMC7669432.
[13]
Blei F. Kaposiform hemangioendothelioma:therapeutic efficacy for an enigmatic diagnosis[J]. Pediatr Blood Cancer, 2015, 62(4):551-552. DOI:10.1002/pbc.25365. PMID:25559734.
[14]
Yao W, Li K, Wang ZP, et al. Comparison of efficacy and safety of corticosteroid and vincristine in treating Kaposiform hemangioendothelioma and tufted angioma:a multicenter prospective randomized controlled clinical trial[J]. J Dermatol, 2021, 48(5):576-584. DOI:10.1111/1346-8138.15767. PMID:33608936.
[15]
Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies[J]. Eur J Pediatr, 2015, 174(12):1579-1584. DOI:10.1007/s00431-015-2572-y. PMID:26040705.
Guo L, Wu CH, Song D, et al. Transcatheter arterial sclerosing embolization for the treatment of giant propranolol-resistant infantile hemangiomas in the parotid region[J]. J Vasc Interv Radiol, 2021, 32(2):293-298. DOI:10.1016/j.jvir.2020.09.029. PMID:33221193.
[19]
Brill R, Uller W, Huf V, et al. Additive value of transarterial embolization to systemic sirolimus treatment in Kaposiform hemangioendothelioma[J]. Int J Cancer, 2021, 148(9):2345-2351. DOI:10.1002/ijc.33406. PMID:33231291.
[20]
Wu YH, Qiu RL, Zeng LX, et al. Effective surgical treatment of life-threatening huge vascular anomalies associated with thrombocytopenia and coagulopathy in infants unresponsive to drug therapy[J]. BMC Pediatr, 2020, 20(1):187. DOI:10.1186/s12887-020-02093-x. PMID:32340603. PMCID:PMC7187498.
